Vaccinex's Next Generation ActivMAb Technology Published In mAbs, A Leading Biotech Journal, And Validated In OmniAb Proof-Of-Concept Collaboration
Portfolio Pulse from Benzinga Newsdesk
Vaccinex, Inc. (NASDAQ:VCNX) has announced a new publication in the journal mAbs, describing a novel way in which its proprietary ActivMAb® poxvirus platform can enable the presentation of high complexity, hard-to-drug proteins as targets for antibody discovery. The technology was successfully applied in a proof-of-concept evaluation by OmniAb to select antibodies against ion channel and chemokine receptor proteins in transgenic animals.
September 28, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaccinex's new publication and successful application of its ActivMAb technology in OmniAb's proof-of-concept evaluation could potentially boost its reputation and stock value.
The successful application of Vaccinex's ActivMAb technology in OmniAb's proof-of-concept evaluation demonstrates the potential of the technology in antibody discovery. This could attract more partnerships and increase the company's value, potentially leading to a rise in its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100